Clinical trials: Progressive Pulmonary Fibrosis
Healthy Subjects
A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.
The study is intended to quantify the effect of co-administration and staggered dosing of AZD5055 and nintedanib on exposures of nintedanib in healthy participants.
- Trial name
- NCT05644600
- Testing
- Nintedanib, AZD5055
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Connective Tissue Diseases, Interstitial Lung Disease
Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases
Connective tissue diseases (CTDs) cover a broad range of systemic rheumatic disorders characterized by abnormal immune activation, chronic inflammatory response, and fibrosis of internal organs.
- Trial name
- COOPERATION1 (NCT07541638)
- Testing
- No experimental intervention (medication or device)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
This pilot randomized controlled trial evaluates the feasibility, acceptability, and accessibility of SUPPORT-T, a digitally delivered palliative care intervention for patients with Progressive Pulmonary Fibrosis (PPF) and their…
- Trial name
- NCT07269262
- Testing
- SUPPORT-T Educational Intervention
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Medical University of South Carolina
Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis
This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.
- Conditions
- Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Trial name
- UPWARD (NCT07722507)
- Testing
- Antifibrotic therapy
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Lung Diseases, Interstitial
INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
The primary objective of this observational study is to investigate the correlation between changes from baseline at 52 weeks in forced vital capacity (FVC) and changes from baseline at 52 weeks in dyspnea score points or cough…
- Trial name
- INREAL (NCT04702893)
- Testing
- Nintedanib
- Where
- 21 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study
This is a cross-sectional study that will be conducted across Japan using an online patient-reported outcome questionnaire. This study tries to find out the attitudes toward and experiences of the emotional and/or social impact…
- Trial name
- NCT07743996
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- Boehringer Ingelheim
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing…
- Trial name
- NCT05139719
- Testing
- HEC585 dose A, HEC585 dose B
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Interstitial Lung Disease, Pulmonary Fibrosis
P4O2 ILD Extension
The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs).
- Conditions
- Interstitial Lung Disease, Pulmonary Fibrosis, Interstitial Lung Fibrosis, IPF
- Trial name
- P4O2-ILD (NCT06644144)
- Testing
- No Interventions
- Where
- Netherlands
- Volunteers
- 450 people
- Sponsor
- Amsterdam UMC, location VUmc
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
- Trial name
- NCT05943535
- Testing
- Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Where
- 165 sites in United States, Argentina and 13 more
- Volunteers
- 698 people
- Sponsor
- United Therapeutics
Pulmonary Fibrosis, Interstitial Lung Disease
Pulmonary Fibrosis Foundation Community Registry
Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members.
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT05382572
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Pulmonary Fibrosis Foundation
Graft Dysfunction, Interstitial Fibrosis
Novartis Everolimus Transition
Transition from tacrolimus based triple therapy with Mycophenolate Mofetil (MMF) and steroids in stable renal transplant patients to low intensity tacrolimus, everolimus and prednisone will be associated with improvement in…
- Trial name
- NCT02096107
- Testing
- Everolimus, Standard of Care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Sarcoidosis, Pulmonary
Pirfenidone for Progressive Fibrotic Sarcoidosis
Study comparing pirfenidone versus placebo for patients with advanced fibrotic sarcoidosis
- Trial name
- PirFS (NCT03260556)
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Cincinnati
Pulmonary Fibrosis
Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis
This study is a prospective observational study for subjects with idiopathic pulmonary fibrosis (IPF) or non-IPF interstitial lung diseases (ILD).
- Trial name
- IS-PPF (NCT06162884)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, Los Angeles
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis
A Trial of HRS-9813 in Healthy Subjects
The study is being conducted to evaluate the safety and pharmacokinetics of HRS-9813 after multiple oral administration in healthy subjects.
- Trial name
- NCT06821464
- Testing
- HRS-9813
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Pulmonary Fibrosis
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of…
- Trial name
- NCT04308681
- Testing
- BMS-986278
- Where
- 119 sites in United States, Argentina and 16 more
- Volunteers
- 403 people
- Sponsor
- Bristol-Myers Squibb
Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary
Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology.
- Conditions
- Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary, Dermatomyositis, Rheumatoid Arthritis
- Trial name
- RMD-mILDer (NCT06732674)
- Testing
- A home monitoring strategy with event driven management
- Where
- Norway
- Volunteers
- 218 people
- Sponsor
- Oslo University Hospital
Lung Diseases, Interstitial
An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options
This Expanded Access Program in Belgium is open to people with different lung diseases. This program provides a medicine called nintedanib to people who have no alternative treatment options.
- Trial name
- NCT04739150
- Testing
- nintedanib
- Where
- 14 sites in Belgium
- Sponsor
- Boehringer Ingelheim
Interstitial Lung Diseases
Anlotinib Capsules in the Treatment for IPF/PF-ILDs
This is an exploratory Phase 2 study evaluating the use of Anlotinib hydrochloride capsules for the treatment of IPF/PF-ILDs, with forced vital capacity (FVC) as the primary efficacy endpoint.
- Trial name
- NCT05828953
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis
Purpose: To demonstrate the safety and efficacy of autologous Lung Spheroid Stem Cells (LSCs) administered by intravenous infusion in patients with idiopathic pulmonary fibrosis Progressive Fibrotic Interstitial Lung Disease.
- Trial name
- HALT-IPF (NCT04262167)
- Testing
- Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill